Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to phosphodiesterase type 5 inhibitors
The Journal of Sexual Medicine · 2025
DOI: 10.1093/jsxmed/qdaf225 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Francois Giuliano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Uro-Andrology Department, R. Poincaré Academic Hospital 92380 Garches, Versailles-Saint Quentin-en-Yvelines University/Paris-Saclay, France. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Sildenafil Citrate, Erectile Dysfunction, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Assistance Publique-Hôpitaux de Paris (Délégation à la Recherche Clinique et à l'Innovation), Programme Hospitalier de Recherche Clinique-PHRC 2020 (Ministère de la Santé), Assistance Publique–Hôpitaux de Paris.
Abstract (Originalsprache)
Background
Studies suggest intracavernosal botulinum toxin A (BTX/A) could improve difficult-to-treat erectile dysfunction (ED) ie with an insufficient response to phosphodiesterase type 5 inhibitors (PDE5-Is).
Aim
To investigate efficacy and safety of intracavernosal injection (ICI) of BTX/A combined with sildenafil 100 mg on demand in patients with ED and insufficient response to PDE5-Is.
Methods
Double-blind, placebo-controlled, multicenter, randomized phase 2 trial to investigate the efficacy and safety of bilateral 0.5 ml ICIs of incobotulinumtoxinA 50 U or placebo, both combined with sildenafil 100 mg on demand in men with ED and insufficient response to sildenafil 100 mg on demand. The inclusion criteria were International Index of Erectile Function-Erectile Function (IIEF-EF) domain score < 17 and >50% of attempts at sexual intercourse unsuccessful during a 4-week open-label run-in phase with sildenafil 100 mg on demand. Outcomes Mean change in IIEF-EF score and the proportion of “Yes” responses to Sexual Encounter Profile (SEP)-Q2 (ability to penetrate) and SEP-Q3 (ability to maintain an erection for successful intercourse) at 3 months.
Results
Out of 226 patients screened, 165 patients were randomized (mean age: 60.1 years, mean IIEF-EF on sildenafil 100 mg: 11.1). Intention-to-treat (ITT) analysis showed no significant improvement in IIEF-EF score with incobotulinumtoxinA 100 U combined with sildenafil 100 mg at 3 months. IncobotulinumtoxinA 100 U improved penetration (SEP-Q2) and erection maintenance (SEP-Q3), but not significantly. These results were confirmed by the complete-case and per-protocol analyses. Adjusted analysis for 100% adherence to sildenafil 100 mg showed a significant interaction effect (P = .032), suggesting greater IIEF-EF improvement in fully compliant patients. The safety profile was positive. Clinical Implications IncobotulinumtoxinA 100 U combined with sildenafil 100 mg on demand is safe; however, there is yet no robust evidence to support its use to treat ED. Strengths and Limitations Main strengths include the double-blind, placebo-controlled design, which was preceded by an open-label run-in phase, a 3-month follow-up, the use of ITT analysis and meaningful outcome measures. Limitations include no adherence to sildenafil (28%), inconsistent clamping at the penile crus post-incobotulinumtoxinA injection, and an underpowered sample size due to an overestimated treatment effect.
Conclusion
Despite negative ITT effectiveness results, this study demonstrated the safety of intracavernosal BTX/A. The results raise hypotheses regarding its potential role in combination with PDE5-Is, warranting further investigation. Future trials should refine patient selection and injection technique, assess dose-response effects, and improve protocol adherence to yield more reliable results for ED resistant to PDE5-Is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuro-Uro-Andrology Department, R. Poincaré Academic Hospital 92380 Garches, Versailles-Saint Quentin-en-Yvelines University/Paris-Saclay, France.
- Urology Department, Academic Hospital Pitié-Salpétrière, AP-HP, 75014 Paris, Sorbonne Université, France.
- Urology Department, Foch Hospital,92073 Suresnes, Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay, France.
- Department of Urology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon Est and Lyon Sud Medical School, Claude Bernard University Lyon 1, 69152 Pierre-Bénite, France.
- Urology Clinique Mutualiste de la Porte de l'Orient, 56100 Lorient, France.
- Urology and Andrology Department, Nimes University Hospital, 30000 Nimes, France.
Förderung
- Assistance Publique-Hôpitaux de Paris (Délégation à la Recherche Clinique et à l'Innovation)
- Programme Hospitalier de Recherche Clinique-PHRC 2020 (Ministère de la Santé)
- Assistance Publique–Hôpitaux de Paris
- Programme Hospitalier de Recherche Clinique–PHRC 2020
Zitieren
APA
Giuliano, F., Denormandie, A. C., Madec, F. X., Carnicelli, D., Graziana, J. P., Droupy, S., Marcelli, F., Gassama, M., Grimaldi, L., & MENOX study group (2025). Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to phosphodiesterase type 5 inhibitors. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf225
Vancouver
Giuliano F, Denormandie AC, Madec FX, Carnicelli D, Graziana JP, Droupy S, et al. Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to phosphodiesterase type 5 inhibitors. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf225
BibTeX
@article{Giuliano2025,
author = {Giuliano, Francois and Denormandie, Anne-Charlotte and Madec, Francois-Xavier and Carnicelli, Damien and Graziana, Jean-Pierre and Droupy, Stéphane and Marcelli, Francois and Gassama, Malamine and Grimaldi, Lamiae and MENOX study group, MENOX study group},
title = {Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to phosphodiesterase type 5 inhibitors},
journal = {The Journal of Sexual Medicine},
year = {2025},
doi = {10.1093/jsxmed/qdaf225}
}
EUVIMED